Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | RHOC | P08134 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.81 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.76 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.76 |
| ▸ | PDE6D | O43924 | 4/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138508 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13629742 | 0.94 | HMGCR (0.77) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13118084 | 0.94 | HMGCR (0.77) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL3535164 | 0.94 | HMGCR (0.91) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL3533997 | 0.94 | HMGCR (0.91) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL3533994 | 0.94 | HMGCR (0.91) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13900416 | 0.93 | HMGCR (0.78) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13885721 | 0.92 | HMGCR (0.75) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28403477 | 0.91 | HMGCR (0.68) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28403474 | 0.91 | HMGCR (0.68) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | disclosed |
| US-20050197501-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1425287-A4 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMA (IL) | 2005-09-07 | — | — | EP | disclosed |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | NIDDAM-HILDESHEIM VALERIE (IL) | 2004-09-09 | — | — | US | disclosed |
| US-6777552-B2 | FROM AN ESTER DERIVATIVE OR PROTECTED ESTER DERIVATIVE OF THE STATIN BY USING CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| EP-1425287-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-06-19 | — | — | US | disclosed |
| WO-2003016317-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-27 | — | — | WO | disclosed |
| US-5124482-A | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| US-5097045-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| US-4681893-A | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197501-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885SLCO1B1 806/4885ABCB11 1132/4885 |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885SLCO1B1 806/4885ABCB11 1132/4885 |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | HMGCR 1/4885SLCO1B1 806/4885ABCB11 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.